Of course I’m familiar with the stock, and of course, as a self-proclaimed high-risk investor, I’d already invested in it. I bought in at under 4 on September 25 and sold out again in October with a quick 15% gain. I was clearly too impatient back then; otherwise, I would have ridden the hype in November. In general, though, I still find the strategy interesting. Getting in early can be lucrative.
•
22
•
1Mo
@Multibagger Yeah, getting in at under $4 and then selling at a 15% gain is, of course, disappointing in hindsight. But you can never know that in advance, of course. 😂 My patience definitely could have been rewarded a little more there. But that’s exactly what I find so exciting about CV: In my opinion, the story is far from over. I see the stock more as a long-term bet on medtech and AI, and not necessarily as a quick trade.
I’m curious to see if you’ll buy in again this time—and if so, at what price? 😄
I’m curious to see if you’ll buy in again this time—and if so, at what price? 😄
•
11
•